William Blair’s biopharma investment banking team’s Quarterly Rx was cited by the The Wall Street Journal in its coverage of IPO activity and other investment trends in the sector.
Investment Banking
The Wall Street Journal Cites Biopharma Investment Banking’s Quarterly Report
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
-
The Pet Supplements Industry Is Booming and Requires More Capacity and Capabilities
The pet supplements industry is on track for strong continued growth. Meeting future demand will require both additional capacity and enhanced capabilities to stay ahead of intensifying competition—creating opportunities for investors.
-
William Blair Serves as Exclusive Financial Advisor to Vantaca in its Minority Growth Investment From Cove Hill Partners
William Blair acted as the exclusive financial advisor to Vantaca in connection with its $300-plus million minority growth investment from Cove Hill Partners at a $1.25 billion valuation.
-
How Embedded Finance Drives Enterprise Value and Increases Multiples for SaaS Platforms
Embedded finance continues to be a highly promising growth opportunity for software platforms looking to expand into multiproduct businesses that allow their customers to have an integrated user experience and consolidate vendors.